This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| bigram | frequency |
|---|---|
| health care | 111 |
| convalescent plasma | 93 |
| acute respiratory | 84 |
| respiratory syndrome | 63 |
| severe acute | 60 |
| mayo clinic | 59 |
| coronavirus disease | 57 |
| clin proc | 40 |
| mayo clin | 40 |
| doc id | 39 |
| cord uid | 39 |
| proc doi | 39 |
| novel coronavirus | 36 |
| public health | 35 |
| united states | 35 |
| contact tracing | 32 |
| care workers | 31 |
| mechanical ventilation | 30 |
| new york | 29 |
| hospitalized patients | 29 |
| severe covid | 25 |
| social distancing | 22 |
| health organization | 21 |
| ill patients | 21 |
| syndrome coronavirus | 21 |
| world health | 21 |
| primary care | 21 |
| converting enzyme | 20 |
| systematic review | 20 |
| infectious diseases | 20 |
| respiratory failure | 20 |
| risk factors | 19 |
| vital signs | 18 |
| myocardial injury | 17 |
| intensive care | 17 |
| critically ill | 17 |
| clinical course | 16 |
| care providers | 15 |
| randomized controlled | 15 |
| plasma transfusion | 15 |
| disease control | 15 |
| emergency department | 15 |
| hong kong | 15 |
| substance use | 14 |
| york city | 14 |
| distress syndrome | 14 |
| clinical guidance | 14 |
| mortality rate | 14 |
| respiratory distress | 14 |
| avian influenza | 13 |
| use disorders | 13 |
| healthcare workers | 13 |
| high risk | 13 |
| lung injury | 13 |
| alcohol use | 13 |
| care unit | 13 |
| segment elevation | 13 |
| myocardial infarction | 12 |
| hearing loss | 12 |
| care delivery | 12 |
| use disorder | 12 |
| clinical characteristics | 12 |
| pd deficiency | 12 |
| receptor blockers | 11 |
| day mortality | 11 |
| patients may | 11 |
| cardiovascular disease | 11 |
| clinical features | 11 |
| clinical trials | 10 |
| clinical outcomes | 10 |
| patient care | 10 |
| cardiac events | 10 |
| case series | 10 |
| angiotensin converting | 10 |
| patients admitted | 10 |
| acei arb | 10 |
| sud treatment | 10 |
| disease spread | 10 |
| clinical trial | 10 |
| community engagement | 10 |
| protective equipment | 10 |
| ecg abnormalities | 9 |
| personal protective | 9 |
| respiratory infections | 9 |
| sars coronavirus | 9 |
| symptom onset | 9 |
| disease severity | 9 |
| enzyme inhibitors | 9 |
| respiratory vitals | 9 |
| mental health | 9 |
| expression levels | 9 |
| universal masking | 9 |
| cytokine storm | 9 |
| acute myocardial | 9 |
| abnormal respiratory | 9 |
| index case | 8 |
| atrial fibrillation | 8 |
| vital sign | 8 |
| heart failure | 8 |
| medical school | 8 |
| patients hospitalized | 8 |
| care organizations | 8 |
| tmprss expression | 8 |
| viral transmission | 8 |
| fatty liver | 8 |
| renin angiotensin | 8 |
| air travel | 8 |
| respiratory vital | 8 |
| incubation period | 8 |
| critical illness | 8 |
| infected patients | 8 |
| controlled trial | 8 |
| angiotensin system | 8 |
| right ventricular | 8 |
| infection control | 8 |
| controlled trials | 8 |
| universal shelter | 8 |
| threatening covid | 7 |
| cohort study | 7 |
| early intubation | 7 |
| extensively drug | 7 |
| artificial intelligence | 7 |
| care system | 7 |
| expanded access | 7 |
| respiratory rate | 7 |
| among patients | 7 |
| million people | 7 |
| clinic proceedings | 7 |
| clinical practice | 7 |
| medical education | 7 |
| global pandemic | 7 |
| supply chain | 7 |
| confirmed covid | 7 |
| patients infected | 7 |
| resistant tuberculosis | 7 |
| alcohol consumption | 7 |
| transfused patients | 7 |
| infectious disease | 7 |
| phosphate dehydrogenase | 7 |
| angiotensin receptor | 7 |
| serious adverse | 7 |
| real time | 7 |
| respiratory tract | 7 |
| case fatality | 6 |
| type mi | 6 |
| organizing pneumonia | 6 |
| standard oxygen | 6 |
| immune system | 6 |
| family members | 6 |
| response rates | 6 |
| ejection fraction | 6 |
| septic shock | 6 |
| increased risk | 6 |
| adverse events | 6 |
| arb use | 6 |
| invasive mechanical | 6 |
| task force | 6 |
| control measures | 6 |
| vulnerable populations | 6 |
| repeat testing | 6 |
| urgent need | 6 |
| addiction treatment | 6 |
| virtual visits | 6 |
| digital contact | 6 |
| east respiratory | 6 |
| opioid use | 6 |
| healthcare professionals | 6 |
| seven days | 6 |
| many patients | 6 |
| access program | 6 |
| middle east | 6 |
| resistant tb | 6 |
| drug administration | 6 |
| coronary artery | 6 |
| immune response | 5 |
| exposure risk | 5 |
| obstructive pulmonary | 5 |
| will also | 5 |
| anecdotal evidence | 5 |
| critical care | 5 |
| us fda | 5 |
| blood banking | 5 |
| methodological standards | 5 |
| hypoxemic respiratory | 5 |
| respiratory infection | 5 |
| left ventricular | 5 |
| lack thereof | 5 |
| health authorities | 5 |
| infected individuals | 5 |
| primary endpoints | 5 |
| general public | 5 |
| index cases | 5 |
| surveillance case | 5 |
| digital health | 5 |
| ace expression | 5 |
| recruitment strategy | 5 |
| donor recruitment | 5 |
| unapproved drugs | 5 |
| standard precautions | 5 |
| acute hypoxemic | 5 |
| immunodeficiency virus | 5 |
| outcomes among | 5 |
| health emergency | 5 |
| treatment considerations | 5 |
| reactive protein | 5 |
| wall motion | 5 |
| human immunodeficiency | 5 |
| supportive care | 5 |
| angiotensin ii | 5 |
| positive pressure | 5 |
| smoking cessation | 5 |
| increased severity | 5 |
| st segment | 5 |
| body mass | 5 |
| adult inpatients | 5 |
| multiple organ | 5 |
| adoption rate | 5 |
| disease prevention | 5 |
| three ecg | 5 |
| ventilatory support | 5 |
| artery disease | 5 |
| influenza virus | 5 |
| plasma therapy | 5 |
| viral infections | 5 |
| interim guidance | 5 |
| clinic strategies | 5 |
| person treatment | 5 |
| york times | 5 |
| acute coronary | 5 |
| virtual care | 5 |
| care systems | 5 |
| cardiac injury | 5 |
| data capture | 5 |
| generating procedures | 5 |
| nasal cannula | 5 |
| aldosterone system | 5 |
| human convalescent | 5 |
| oxygen saturation | 5 |
| mycobacterium tuberculosis | 5 |
| medical care | 5 |
| regulatory changes | 5 |
| higher mortality | 5 |
| future pandemics | 5 |
| inflammatory response | 5 |
| primary outcome | 5 |
| oxygen therapy | 5 |
| pulmonary disease | 5 |
| polymerase chain | 5 |
| invasive ventilation | 5 |
| confirmed cases | 5 |
| drugs initiative | 5 |
| helmet cpap | 5 |
| quality evidence | 5 |
| first case | 5 |
| chronic obstructive | 5 |
| susceptible population | 5 |
| pressure ventilation | 5 |
| prognostic capacity | 5 |
| blood donation | 5 |
| system inhibitors | 5 |
| worse outcomes | 5 |
| drug resistance | 5 |
| chain reaction | 5 |
| eligible donors | 5 |
| critical review | 5 |
| observational studies | 4 |
| recruitment survey | 4 |
| retrospective cohort | 4 |
| adverse outcomes | 4 |
| primary endpoint | 4 |
| infectious agents | 4 |
| personal sound | 4 |
| peer review | 4 |
| care may | 4 |
| patient satisfaction | 4 |
| electronic health | 4 |
| care facilities | 4 |
| virtual reality | 4 |
| lower respiratory | 4 |
| nosocomial transmission | 4 |
| patients transfused | 4 |
| west nile | 4 |
| sars cov | 4 |
| cardiac imaging | 4 |
| evidence base | 4 |
| scientific publications | 4 |
| tb cases | 4 |
| suspected covid | 4 |
| clinical presentation | 4 |
| within hours | 4 |
| immediately available | 4 |
| abnormal ecg | 4 |
| observational study | 4 |
| laboratory values | 4 |
| pcr testing | 4 |
| human services | 4 |
| remains unclear | 4 |
| plasma donors | 4 |
| pandemic date | 4 |
| individuals isolated | 4 |
| sound amplification | 4 |
| service center | 4 |
| chronic kidney | 4 |
| spread rapidly | 4 |
| past decade | 4 |
| group treatment | 4 |
| thrombotic events | 4 |
| coronary occlusion | 4 |
| may also | 4 |
| reference verification | 4 |
| low risk | 4 |
| unclear whether | 4 |
| emerging infectious | 4 |
| amplification products | 4 |
| recovered covid | 4 |
| plasma donor | 4 |
| significant differences | 4 |
| innate immune | 4 |
| safety update | 4 |
| acral sites | 4 |
| severe disease | 4 |
| southern china | 4 |
| vast majority | 4 |
| indicates heart | 4 |
| respiratory droplets | 4 |
| median time | 4 |
| urine drug | 4 |
| virus infection | 4 |
| reperfusion therapy | 4 |
| inflammatory processes | 4 |
| national security | 4 |
| telehealth services | 4 |
| multivariable regression | 4 |
| catheterization laboratory | 4 |
| dehydrogenase deficiency | 4 |
| exposed individuals | 4 |
| teaching rounds | 4 |
| infected persons | 4 |
| blood cell | 4 |
| studies published | 4 |
| presenting characteristics | 4 |
| bird flu | 4 |
| nile virus | 4 |
| emergency room | 4 |
| health systems | 4 |
| insufficient evidence | 4 |
| kidney disease | 4 |
| seattle region | 4 |
| reduce mortality | 4 |
| organ failure | 4 |
| randomized trials | 4 |
| laboratory test | 4 |
| research electronic | 4 |
| african americans | 4 |
| surgical environment | 4 |
| alcohol dependence | 4 |
| normal respiratory | 4 |
| dysfunction failure | 4 |
| review time | 4 |
| one study | 4 |
| new human | 4 |
| electronic data | 4 |
| adoption rates | 4 |
| system blockers | 4 |
| cognitive biases | 4 |
| factors associated | 4 |
| medication shortages | 4 |
| higher among | 4 |
| banking community | 4 |
| disease among | 4 |
| prognostic value | 4 |
| recent study | 4 |
| obstructive coronary | 4 |
| mortality rates | 4 |
| four hours | 4 |
| severe cases | 4 |
| automated contact | 4 |
| abstinence rates | 4 |
| regional wall | 4 |
| infected pneumonia | 4 |
| occurred within | 4 |
| within four | 4 |
| additional data | 4 |
| organ dysfunction | 4 |
| susceptible individuals | 4 |
| sign abnormalities | 4 |
| blood pressure | 3 |
| mean age | 3 |
| treat covid | 3 |
| cardiac arrest | 3 |
| convalescent sera | 3 |
| increased mortality | 3 |
| filtering face | 3 |
| death rate | 3 |
| hospital staff | 3 |
| us department | 3 |
| increased susceptibility | 3 |
| federal government | 3 |
| international collaboration | 3 |
| chinese center | 3 |
| general population | 3 |
| lung function | 3 |
| acute lung | 3 |
| brief interventions | 3 |
| genome sequence | 3 |
| viral loads | 3 |
| prone position | 3 |
| acute ischemic | 3 |
| patients including | 3 |
| viable option | 3 |
| medical attention | 3 |
| china characterization | 3 |
| absolute lymphocyte | 3 |
| influenza pneumonia | 3 |
| among older | 3 |
| data provide | 3 |
| liver disorders | 3 |
| many host | 3 |
| college admissions | 3 |
| serologic testing | 3 |
| task forces | 3 |
| hospitalization rates | 3 |
| preliminary data | 3 |
| infectious agent | 3 |
| fewer individuals | 3 |
| required mechanical | 3 |
| epithelial cells | 3 |
| diabetes mellitus | 3 |
| tract infection | 3 |
| first reported | 3 |
| confidence interval | 3 |
| health records | 3 |
| sars outbreak | 3 |
| mechanically ventilated | 3 |
| type myocardial | 3 |
| prevention strategies | 3 |
| inflammatory cytokines | 3 |
| two contiguous | 3 |
| medical students | 3 |
| older adults | 3 |
| sars returns | 3 |
| baseline characteristics | 3 |
| quality studies | 3 |
| within rows | 3 |
| surgical masks | 3 |
| created using | 3 |
| older males | 3 |
| makeshift masks | 3 |
| risk stratification | 3 |
| eligibility criteria | 3 |
| severe illness | 3 |
| person care | 3 |
| hospitalized adults | 3 |
| fatality rates | 3 |
| text messaging | 3 |
| less accessible | 3 |
| states covid | 3 |
| office visit | 3 |
| standard blood | 3 |
| early diagnosis | 3 |
| gender disparities | 3 |
| recent reports | 3 |
| hand hygiene | 3 |
| mathematical theory | 3 |
| help us | 3 |
| spanish influenza | 3 |
| respiratory symptoms | 3 |
| specific tissues | 3 |
| based dashboard | 3 |
| long term | 3 |
| line drugs | 3 |
| great interest | 3 |
| many providers | 3 |
| based treatment | 3 |
| gtex data | 3 |
| diseases society | 3 |
| health crisis | 3 |
| care services | 3 |
| expression data | 3 |
| care units | 3 |
| plasma donation | 3 |
| point estimate | 3 |
| interested volunteers | 3 |
| care institutions | 3 |
| hospital admission | 3 |
| new digital | 3 |
| healthcare provider | 3 |
| immune responses | 3 |
| extreme outliers | 3 |
| us covid | 3 |
| human pathogens | 3 |
| interactive web | 3 |
| hospital mortality | 3 |
| significantly higher | 3 |
| influenza pandemic | 3 |
| face masks | 3 |
| contiguous leads | 3 |
| nan coronavirus | 3 |
| safety indicators | 3 |
| admissions personnel | 3 |
| data abstraction | 3 |
| reports suggest | 3 |
| resource allocation | 3 |
| south africa | 3 |
| working group | 3 |
| several reasons | 3 |
| telehealth visits | 3 |
| hubei province | 3 |
| ii receptor | 3 |
| randomized clinical | 3 |
| vulnerable communities | 3 |
| became infected | 3 |
| texting interventions | 3 |
| city area | 3 |
| clinical research | 3 |
| induced lung | 3 |
| severe sars | 3 |
| cancer patients | 3 |
| stress disorder | 3 |
| training programs | 3 |
| negative results | 3 |
| clinical specimens | 3 |
| chronic illness | 3 |
| ventricular hypertrophy | 3 |
| current pandemic | 3 |
| weak recommendation | 3 |
| host cells | 3 |
| protease inhibitors | 3 |
| paramount importance | 3 |
| endothelial dysfunction | 3 |
| hearing aids | 3 |
| initial report | 3 |
| fatality rate | 3 |
| ehr implementations | 3 |
| even though | 3 |
| coronary angiography | 3 |
| several factors | 3 |
| infection date | 3 |
| medical training | 3 |
| isolation measures | 3 |
| global burden | 3 |
| current covid | 3 |
| upper respiratory | 3 |
| hepatic steatosis | 3 |
| randomized trial | 3 |
| continuing care | 3 |
| frequency modulation | 3 |
| china coronavirus | 3 |
| successful implementation | 3 |
| ventricular overload | 3 |
| ccl activation | 3 |
| review article | 3 |
| ahrf due | 3 |
| behavioral health | 3 |
| smallpox virus | 3 |
| lymphocyte count | 3 |
| commercial aircraft | 3 |
| surgical area | 3 |
| risks associated | 3 |
| short supply | 3 |
| clinical symptoms | 3 |
| mediterranean region | 3 |
| late december | 3 |
| pressure rooms | 3 |
| injectable naltrexone | 3 |
| pandemic influenza | 3 |
| nationwide analysis | 3 |
| surgical mask | 3 |
| lactate dehydrogenase | 3 |
| liver function | 3 |
| hospital sector | 3 |
| drug therapy | 3 |
| nippv treatment | 3 |
| lung infiltrates | 3 |
| using telehealth | 3 |
| preliminary report | 3 |
| drinks per | 3 |
| ras inhibitors | 3 |
| logistic regression | 3 |
| trial results | 3 |
| requiring mechanical | 3 |
| full lockdown | 3 |
| key safety | 3 |
| european centre | 3 |
| viral infection | 3 |
| multiple tissues | 3 |
| cardiac catheterization | 3 |
| via telehealth | 3 |
| targeted self | 3 |
| important lessons | 3 |
| face mask | 3 |
| several studies | 3 |
| commonly used | 3 |
| severe respiratory | 3 |
| user adoption | 3 |
| urine test | 3 |
| may provide | 3 |
| disease pandemic | 3 |
| going forward | 3 |
| time pressure | 3 |
| subsequent testing | 3 |
| new call | 3 |
| airway pressure | 3 |
| among others | 3 |
| management strategies | 3 |
| related lung | 3 |
| pcr assays | 3 |
| chinese authorities | 3 |
| retrospective case | 3 |
| month outcomes | 3 |
| pd deficient | 3 |
| prone positioning | 3 |
| current evidence | 3 |
| several countries | 3 |
| mitigate disease | 3 |
| previous studies | 3 |
| motion abnormalities | 3 |
| circulating levels | 3 |
| cardiac involvement | 3 |
| airborne transmission | 3 |
| adverse cardiac | 3 |
| chest radiograph | 3 |
| north america | 3 |
| term outcomes | 3 |
| clinical settings | 3 |
| effective therapies | 3 |
| coronavirus pandemic | 3 |
| least one | 3 |
| patients presenting | 3 |
| emerging infections | 3 |
| tissue expression | 3 |
| invasive positive | 3 |
| community members | 3 |
| us food | 3 |
| reduce exposure | 3 |
| donor center | 3 |
| drs choo | 3 |
| drug efficacy | 3 |
| blood donor | 3 |
| effective communication | 3 |
| drug supply | 3 |
| large droplets | 3 |
| coronavirus sars | 3 |
| health equity | 3 |
| data regarding | 3 |
| respiratory viral | 3 |
| made available | 3 |
| several limitations | 3 |
| mortality compared | 3 |
| clinical improvement | 3 |
| traced contacts | 3 |
| track covid | 3 |
| management guidance | 3 |
| clinic blood | 3 |
| donate convalescent | 3 |
| virtual environment | 3 |
| human pathogen | 3 |
| fibrillation flutter | 3 |
| receptor antagonists | 3 |
| circulatory overload | 3 |
| diagnostic stewardship | 3 |
| poor prognosis | 3 |
| lung tissue | 3 |
| civilian population | 3 |
| donor eligibility | 3 |
| injury key | 3 |
| host tissues | 3 |
| transfusion form | 3 |
| presenting vital | 3 |
| cardiovascular implications | 2 |
| treatment campaign | 2 |
| avian strain | 2 |
| two respiratory | 2 |
| includes sub | 2 |
| containing covid | 2 |
| hfnc compared | 2 |
| particulate air | 2 |
| allowed mayo | 2 |
| cardiovascular presentations | 2 |
| sinus rhythm | 2 |
| standard deviation | 2 |
| add additional | 2 |
| targeting tmprss | 2 |
| now known | 2 |
| close contacts | 2 |
| high efficiency | 2 |
| workers caring | 2 |
| initiative programs | 2 |
| received treatment | 2 |
| chronic lymphocytic | 2 |
| use ai | 2 |
| infection cimetidine | 2 |
| processing specimens | 2 |
| high mortality | 2 |
| infections caused | 2 |
| treatment review | 2 |
| urine testing | 2 |
| potential benefits | 2 |
| treatment regimens | 2 |
| financial sustainability | 2 |
| cytotoxic cd | 2 |
| sixth vital | 2 |
| people worldwide | 2 |
| face piece | 2 |
| manage patients | 2 |
| rapid clinical | 2 |
| unnecessary exposure | 2 |
| us hospitals | 2 |
| ms indicates | 2 |
| virtual interactions | 2 |
| health system | 2 |
| predictive modeling | 2 |
| guide practice | 2 |
| exposure alert | 2 |
| prognostic factors | 2 |
| associated circulatory | 2 |
| effort will | 2 |
| including patients | 2 |
| healthcare organizations | 2 |
| hospitalized subjects | 2 |
| care setting | 2 |
| acei arbs | 2 |
| ecg provides | 2 |
| known covid | 2 |
| acute infectious | 2 |
| improper use | 2 |
| sobering statistics | 2 |
| nippv i | 2 |
| initial ecgs | 2 |
| receiving medical | 2 |
| new vaccine | 2 |
| molecular biology | 2 |
| communications commission | 2 |
| failure vs | 2 |
| including lung | 2 |
| overall comparable | 2 |
| pcr assay | 2 |
| sfc hal | 2 |
| provided invaluable | 2 |
| year inside | 2 |
| present study | 2 |
| reduce risks | 2 |
| virus among | 2 |
| common symptoms | 2 |
| become known | 2 |
| hb fvgem | 2 |
| drug prices | 2 |
| cc oyiwp | 2 |
| highly virulent | 2 |
| center team | 2 |
| highest expression | 2 |
| nbc news | 2 |
| requiring intravenous | 2 |
| hfpef indicates | 2 |
| severity among | 2 |
| deficient cells | 2 |
| find innovative | 2 |
| recruit eligible | 2 |
| endotracheal tube | 2 |
| severe systemic | 2 |
| isolation quarantine | 2 |
| nyc health | 2 |
| respiratory therapists | 2 |
| italian novel | 2 |
| reverse transcriptase | 2 |
| acep covid | 2 |
| clinical procedures | 2 |
| oxidative stress | 2 |
| graphical representation | 2 |
| occurring within | 2 |
| sae form | 2 |
| determine whether | 2 |
| press release | 2 |
| virtual meetings | 2 |
| death rates | 2 |
| cytokine responses | 2 |
| patient placement | 2 |
| ongoing pandemic | 2 |
| workers initially | 2 |
| machine learning | 2 |
| funding sources | 2 |
| site adaptive | 2 |
| necrosis factor | 2 |
| patients found | 2 |
| amoy gardens | 2 |
| calculated using | 2 |
| almost completely | 2 |
| change management | 2 |
| patient safety | 2 |
| medical interventions | 2 |
| exotic african | 2 |
| communicable diseases | 2 |
| study completion | 2 |
| care service | 2 |
| rapid development | 2 |
| composite outcome | 2 |
| potential treatment | 2 |
| regulatory barriers | 2 |
| box plots | 2 |
| guiding resource | 2 |
| recent global | 2 |
| community developed | 2 |
| medical literature | 2 |
| using ai | 2 |
| liver disease | 2 |
| mortality events | 2 |
| health interventions | 2 |
| provide information | 2 |
| met criteria | 2 |
| human influenza | 2 |
| study provides | 2 |
| former soviet | 2 |
| differences noted | 2 |
| protein kinase | 2 |
| may become | 2 |
| mg dl | 2 |
| expiratory circuit | 2 |
| hillbilly elegy | 2 |
| enforce isolation | 2 |
| virtual medical | 2 |
| black man | 2 |
| less pronounced | 2 |
| silver lining | 2 |
| vijay rajaram | 2 |
| preserved ejection | 2 |
| deaths weekly | 2 |
| hypertension hospitalized | 2 |
| sars epidemic | 2 |
| many health | 2 |
| st elevations | 2 |
| imaging become | 2 |
| rapid triage | 2 |
| study protocol | 2 |
| group based | 2 |
| directly related | 2 |
| deceased patients | 2 |
| protecting healthcare | 2 |
| infection now | 2 |
| study including | 2 |
| routinely used | 2 |
| healthcare system | 2 |
| following key | 2 |
| current literature | 2 |
| medical system | 2 |
| bibliographic data | 2 |
| resistant staphylococcus | 2 |
| neutralizing antibodies | 2 |
| aceis arbs | 2 |
| cov appears | 2 |
| initial test | 2 |
| lupus erythematosus | 2 |
| dendritic cell | 2 |
| segment abnormalities | 2 |
| retrospective study | 2 |
| treatment programs | 2 |
| facilitate patient | 2 |
| common rhythm | 2 |
| disease center | 2 |
| within health | 2 |
| substantial body | 2 |
| patients using | 2 |
| simplest assessment | 2 |
| tech methods | 2 |
| video based | 2 |
| repeated testing | 2 |
| tb till | 2 |
| flamboyant multiplicity | 2 |
| guangdong province | 2 |
| airborne spread | 2 |
| disease caused | 2 |
| manual contact | 2 |
| produce ventilators | 2 |
| smartphone apps | 2 |
| patients without | 2 |
| alcoholics anonymous | 2 |
| use predictive | 2 |
| air filters | 2 |
| different breathing | 2 |
| national blood | 2 |
| primary vehicle | 2 |
| growing magnitude | 2 |
| intubated patients | 2 |
| obstructive sleep | 2 |
| developed active | 2 |
| outcome beyond | 2 |
| similar approach | 2 |
| model except | 2 |
| dozen countries | 2 |
| excellent sheep | 2 |
| transmission dynamics | 2 |
| probable sars | 2 |
| us adults | 2 |
| diagnostic test | 2 |
| month later | 2 |
| studies suggest | 2 |
| world context | 2 |
| field guide | 2 |
| human beings | 2 |
| indicates electrocardiogram | 2 |
| herpes simplex | 2 |
| flu vaccine | 2 |
| quickly screen | 2 |
| odds ratios | 2 |
| directed echocardiogram | 2 |
| unmet needs | 2 |
| american college | 2 |
| per hour | 2 |
| compares helmet | 2 |
| protection act | 2 |
| place measures | 2 |
| treatment modalities | 2 |
| initial results | 2 |
| important marker | 2 |
| international concern | 2 |
| reduced ejection | 2 |
| temporary easing | 2 |
| early sars | 2 |
| human protein | 2 |
| informatics support | 2 |
| patient factors | 2 |
| help group | 2 |
| confirmed symptomatic | 2 |
| sars cases | 2 |
| red blood | 2 |
| sedimentation rate | 2 |
| requiring supplemental | 2 |
| medical conditions | 2 |
| ecg findings | 2 |
| virtual worlds | 2 |
| engagement activities | 2 |
| hemolytic anemia | 2 |
| persons infected | 2 |
| positive airway | 2 |
| pressor support | 2 |
| recovering covid | 2 |
| high volume | 2 |
| initial reports | 2 |
| ryan haight | 2 |
| personnel alike | 2 |
| fm frequency | 2 |
| prescribing controlled | 2 |
| metabolic syndrome | 2 |
| hospital arrival | 2 |
| sud patients | 2 |
| may result | 2 |
| human infection | 2 |
| nan i | 2 |
| copd indicates | 2 |
| health center | 2 |
| early data | 2 |
| phase iii | 2 |
| small intestine | 2 |
| african rodents | 2 |
| previously published | 2 |
| ecg indicates | 2 |
| government agencies | 2 |
| days since | 2 |
| improve quality | 2 |
| published articles | 2 |
| patients remain | 2 |
| separate roofline | 2 |
| transmembrane protease | 2 |
| better understanding | 2 |
| growing evidence | 2 |
| function tests | 2 |
| indicates millimeters | 2 |
| evaluate whether | 2 |
| chilblains lupus | 2 |
| infected population | 2 |
| primary perniosis | 2 |
| potentially infectious | 2 |
| disease covid | 2 |
| acute infection | 2 |
| driven methodology | 2 |
| elevation depression | 2 |
| close monitoring | 2 |
| fatal outcome | 2 |
| medical records | 2 |
| advanced automated | 2 |
| data available | 2 |
| outcome tended | 2 |
| education quarantine | 2 |
| microphone lanyard | 2 |
| large number | 2 |
| lessons learned | 2 |
| treating physicians | 2 |
| expected benefit | 2 |
| transmission speed | 2 |
| inhalation anthrax | 2 |
| inform exposed | 2 |
| surrogate clinical | 2 |
| rnaseq based | 2 |
| findings need | 2 |
| described male | 2 |
| potentially deleterious | 2 |
| manuscript evaluation | 2 |
| bz ovx | 2 |
| laboratory markers | 2 |
| safety profile | 2 |
| lat latency | 2 |
| study coronavirus | 2 |
| data visualization | 2 |
| direct communication | 2 |
| will depend | 2 |
| described previously | 2 |
| fufd ba | 2 |
| virtual services | 2 |
| study implementation | 2 |
| chemical dependency | 2 |
| age range | 2 |
| telemedicine services | 2 |
| remains critical | 2 |
| person visits | 2 |
| like buprenorphine | 2 |
| airborne particles | 2 |
| using gtex | 2 |
| day period | 2 |
| troponin levels | 2 |
| testing may | 2 |
| one another | 2 |
| death toll | 2 |
| ill covid | 2 |
| health services | 2 |
| large health | 2 |
| telemedicine options | 2 |
| rapid sequence | 2 |
| positive end | 2 |
| china novel | 2 |
| weaponized smallpox | 2 |
| pcr detection | 2 |
| care personnel | 2 |
| contacts will | 2 |
| common among | 2 |
| even greater | 2 |
| among healthcare | 2 |
| high levels | 2 |
| telehealth visit | 2 |
| time locating | 2 |
| increasing use | 2 |
| infectious respiratory | 2 |
| seated within | 2 |
| cases reported | 2 |
| telemental health | 2 |
| severe forms | 2 |
| may prove | 2 |
| sofa score | 2 |
| viral pandemic | 2 |
| ecg done | 2 |
| understanding risk | 2 |
| pilot study | 2 |
| emerging data | 2 |
| ccl team | 2 |
| review panel | 2 |
| authorities reported | 2 |
| survival function | 2 |
| emerging evidence | 2 |
| death among | 2 |
| specific challenges | 2 |
| drug costs | 2 |
| filtration mask | 2 |
| cumulative incidence | 2 |
| tool developed | 2 |
| based interventions | 2 |
| related serious | 2 |
| greatest risk | 2 |
| ckd indicates | 2 |
| secondary perniosis | 2 |
| risk patients | 2 |
| sore throat | 2 |
| select cases | 2 |
| clinical presentations | 2 |
| cov replication | 2 |
| computed tomography | 2 |
| reduced alcohol | 2 |
| develop strategies | 2 |
| effective triage | 2 |
| clinical study | 2 |
| emergency orders | 2 |
| medical facility | 2 |
| pulmonary infiltrates | 2 |
| individuals will | 2 |
| beta coronaviruses | 2 |
| universal containment | 2 |
| flow rates | 2 |
| emerging pathogens | 2 |
| first seven | 2 |
| health resources | 2 |
| health found | 2 |
| guidance continues | 2 |
| highly contagious | 2 |
| physical distancing | 2 |
| risk factor | 2 |
| social consequences | 2 |
| available early | 2 |
| chinese physician | 2 |
| cad indicates | 2 |
| molecular testing | 2 |
| myocardial involvement | 2 |
| exchanges per | 2 |
| easily applied | 2 |
| widespread implementation | 2 |
| ventricular ejection | 2 |
| dgxn ls | 2 |
| infection prevention | 2 |
| perspective key | 2 |
| providers quickly | 2 |
| considerably longer | 2 |
| minimal symptoms | 2 |
| atlas gtex | 2 |
| based recovery | 2 |
| us prairie | 2 |
| cardiac troponin | 2 |
| dna vaccines | 2 |
| months later | 2 |
| chronic diseases | 2 |
| state licensure | 2 |
| tumor necrosis | 2 |
| patients needing | 2 |
| disease transmission | 2 |
| significantly lower | 2 |
| median systolic | 2 |
| best practices | 2 |
| expression differences | 2 |
| study titles | 2 |
| additional prognostic | 2 |
| south korea | 2 |
| male sex | 2 |
| inc incubation | 2 |
| eye protection | 2 |
| many people | 2 |
| educational conferences | 2 |
| international cooperation | 2 |
| safety metrics | 2 |
| better outcomes | 2 |
| sauq gp | 2 |
| rapidly evolving | 2 |
| time pcr | 2 |
| pandemic caused | 2 |
| patient specimens | 2 |
| current approach | 2 |
| interested potential | 2 |
| invaluable assistance | 2 |
| medical centers | 2 |
| global public | 2 |
| within seven | 2 |
| simplex virus | 2 |
| digital care | 2 |
| body temperature | 2 |
| sd indicates | 2 |
| inflammatory properties | 2 |
| may help | 2 |
| famotidine administration | 2 |
| early triage | 2 |
| accessibility verified | 2 |
| inpatient care | 2 |
| plasma may | 2 |
| testing positive | 2 |
| soviet union | 2 |
| may make | 2 |
| another study | 2 |
| icu admission | 2 |
| van buskirk | 2 |
| solidarity trial | 2 |
| using data | 2 |
| tract symptoms | 2 |
| laboratory services | 2 |
| global sars | 2 |
| exposed health | 2 |
| widely reported | 2 |
| disease burden | 2 |
| one third | 2 |
| sinus tachycardia | 2 |
| motion study | 2 |
| reduced mortality | 2 |
| health competencies | 2 |
| pulmonary involvement | 2 |
| higher rates | 2 |
| potential efficacy | 2 |
| also likely | 2 |
| significant change | 2 |
| older age | 2 |
| patients received | 2 |
| normal circulating | 2 |
| southeast asia | 2 |
| required home | 2 |
| health infrastructure | 2 |
| mask wearing | 2 |
| substantive concerns | 2 |
| care solutions | 2 |
| clinical diagnosis | 2 |
| hospitalized covid | 2 |
| multidisciplinary team | 2 |
| biologic weapon | 2 |
| inflammatory state | 2 |
| safety network | 2 |
| receiving mechanical | 2 |
| working conditions | 2 |
| home monitoring | 2 |
| protein atlas | 2 |
| required intubation | 2 |
| person transmission | 2 |
| strong historical | 2 |
| place orders | 2 |
| increasing numbers | 2 |
| found deaths | 2 |
| abstract objective | 2 |
| early safety | 2 |
| program leadership | 2 |
| admission days | 2 |
| severity scale | 2 |
| antibody titer | 2 |
| fibrinolytic therapy | 2 |
| data immediately | 2 |
| covid respiratory | 2 |
| virus transmission | 2 |
| additional studies | 2 |
| serology test | 2 |
| decision making | 2 |
| risk drinking | 2 |
| invasive care | 2 |
| registry analysis | 2 |
| recently published | 2 |
| heart rate | 2 |
| cenr partnerships | 2 |
| plasmid dna | 2 |
| coronary anatomy | 2 |
| ecg remains | 2 |
| day outcome | 2 |
| included studies | 2 |
| outcomes based | 2 |
| health departments | 2 |
| ace inhibitors | 2 |
| redcap consortium | 2 |
| wgo pml | 2 |
| will allow | 2 |
| sex differences | 2 |
| america guidelines | 2 |
| less effective | 2 |
| must consider | 2 |
| histamine receptor | 2 |
| support strategies | 2 |
| mm hr | 2 |
| high prevalence | 2 |
| prisma guidelines | 2 |
| historical precedent | 2 |
| aerosol generating | 2 |
| plausible face | 2 |
| literature review | 2 |
| social unrest | 2 |
| breathing support | 2 |
| mm indicates | 2 |
| place order | 2 |
| clinical areas | 2 |
| evidence based | 2 |
| patient interviews | 2 |
| reaction testing | 2 |
| later stages | 2 |
| therapy via | 2 |
| approximately million | 2 |
| respiratory samples | 2 |
| monitoring systems | 2 |
| socioeconomic status | 2 |
| vitro studies | 2 |
| corticosteroid therapy | 2 |
| potential explanations | 2 |
| basing risk | 2 |
| infection rate | 2 |
| might also | 2 |
| jtcf mz | 2 |
| liver diseases | 2 |
| ventricular strain | 2 |
| will consider | 2 |
| systolic heart | 2 |
| physician time | 2 |
| apneic oxygenation | 2 |
| controlled substances | 2 |
| agencies will | 2 |
| party payers | 2 |
| vs mm | 2 |
| severity remains | 2 |
| convalescent blood | 2 |
| face evaluation | 2 |
| systematic approach | 2 |
| myocardial ischemia | 2 |
| million individuals | 2 |
| clinical status | 2 |
| disease model | 2 |
| ecgs done | 2 |
| aact app | 2 |
| affects outcome | 2 |
| rapidly expanding | 2 |
| healthcare systems | 2 |
| hopefully will | 2 |
| peak number | 2 |
| high suspicion | 2 |
| sound intensity | 2 |
| lacks input | 2 |
| also limit | 2 |
| dedicated covid | 2 |
| actively involved | 2 |
| via nrb | 2 |
| cigarette smoking | 2 |
| york described | 2 |
| synchronous virtual | 2 |
| remain suspended | 2 |
| flight crew | 2 |
| may benefit | 2 |
| public wear | 2 |
| potential roles | 2 |
| new strain | 2 |
| surveillance program | 2 |
| three hospitals | 2 |
| medical providers | 2 |
| new positive | 2 |
| protease activity | 2 |
| regarding covid | 2 |
| rational approach | 2 |
| wild birds | 2 |
| practice guidelines | 2 |
| thrombotic complications | 2 |
| admission evolves | 2 |
| clinical endpoints | 2 |
| african american | 2 |
| patient needs | 2 |
| preliminary death | 2 |
| infection risk | 2 |
| disease cardiovascular | 2 |
| salivary gland | 2 |
| radiographic evidence | 2 |
| national healthcare | 2 |
| extremely high | 2 |
| tissue damage | 2 |
| highly pathogenic | 2 |
| potential covid | 2 |
| healthcare safety | 2 |
| engaged research | 2 |
| symptomatic conditions | 2 |
| blood products | 2 |
| saes classified | 2 |
| telephone visits | 2 |
| treatment centers | 2 |
| time period | 2 |
| taking acei | 2 |
| supplement vitamin | 2 |
| us civilian | 2 |
| percent increase | 2 |
| critical due | 2 |
| efficiency particulate | 2 |
| fact sheet | 2 |
| seafood market | 2 |
| andrea kim | 2 |
| higher level | 2 |
| available resources | 2 |
| proven cases | 2 |
| tissues may | 2 |
| cohort studies | 2 |
| locating system | 2 |
| conventional oxygen | 2 |
| prairie dogs | 2 |
| interferon alfa | 2 |
| background information | 2 |
| literature supporting | 2 |
| epidemics contributions | 2 |
| roofline exhaust | 2 |
| may explain | 2 |
| lower mortality | 2 |
| mg kg | 2 |
| one month | 2 |
| kxyu nzp | 2 |
| triaging covid | 2 |
| depression includes | 2 |
| may offer | 2 |
| low quality | 2 |
| require even | 2 |
| become infected | 2 |
| coronavirus associated | 2 |
| workflow process | 2 |
| trace contacts | 2 |
| related deaths | 2 |
| platform partners | 2 |
| required higher | 2 |
| substances like | 2 |
| order exposures | 2 |
| per se | 2 |
| clinical evidence | 2 |
| respiratory viruses | 2 |
| will benefit | 2 |
| efficacy study | 2 |
| el hz | 2 |
| factors identified | 2 |
| telemedicine interventions | 2 |
| ards due | 2 |
| saudi arabia | 2 |
| available evidence | 2 |
| investigational compounds | 2 |
| procedural care | 2 |
| potential benefit | 2 |
| minority communities | 2 |
| haight online | 2 |
| essential drugs | 2 |
| particulate matter | 2 |
| federal levels | 2 |
| respiratory disease | 2 |
| traditional treatment | 2 |
| providing translational | 2 |
| validation study | 2 |
| patient contact | 2 |
| dna based | 2 |
| million doses | 2 |
| also needed | 2 |
| ventilated vs | 2 |
| sv zqz | 2 |
| currently available | 2 |
| make us | 2 |
| world greatly | 2 |
| laboratory workers | 2 |
| transmission among | 2 |
| drugs might | 2 |
| air dispersion | 2 |
| principal investigator | 2 |
| concern one | 2 |
| young adults | 2 |
| studies evaluating | 2 |
| location accuracy | 2 |
| website key | 2 |
| different combinations | 2 |
| depressions must | 2 |
| research informatics | 2 |
| social interactions | 2 |
| home induction | 2 |
| human disease | 2 |
| ards days | 2 |
| week later | 2 |
| obesity among | 2 |
| natural history | 2 |
| sequence intubation | 2 |
| individuals expected | 2 |
| additional information | 2 |
| latency period | 2 |
| earliest creatinine | 2 |
| federal communications | 2 |
| similar results | 2 |
| loosening restrictions | 2 |
| effective vaccine | 2 |
| iv alcohol | 2 |
| study period | 2 |
| multiple studies | 2 |
| york department | 2 |
| patients seen | 2 |
| initial presentation | 2 |
| tqjmg qb | 2 |
| prospective randomized | 2 |
| plasma expanded | 2 |
| related saes | 2 |
| intubations occurring | 2 |
| death due | 2 |
| clinical care | 2 |
| widely available | 2 |
| indicates obstructive | 2 |
| indicates standard | 2 |
| allelic variants | 2 |
| air pressure | 2 |
| influenza vaccines | 2 |
| trials using | 2 |
| international community | 2 |
| prevent second | 2 |
| five variables | 2 |
| currently recommended | 2 |
| hfref indicates | 2 |
| high patient | 2 |
| targeted isolation | 2 |
| comprehensive search | 2 |
| remained hospitalized | 2 |
| trial compares | 2 |
| kjq xqs | 2 |
| new pandemic | 2 |
| clinic laboratories | 2 |
| respiratory severity | 2 |
| edible birds | 2 |
| far higher | 2 |
| male gender | 2 |
| pandemic progressed | 2 |
| regional public | 2 |
| millimeter changes | 2 |
| may underestimate | 2 |
| total covid | 2 |
| automated email | 2 |
| series acep | 2 |
| median oxygen | 2 |
| become available | 2 |
| ecg abnormality | 2 |
| crucial due | 2 |
| hospital authority | 2 |
| social determinants | 2 |
| telehealth program | 2 |
| negative air | 2 |
| probable covid | 2 |
| greater chronic | 2 |
| indicates stage | 2 |
| utilizing data | 2 |
| wuhan experience | 2 |
| initial vitals | 2 |
| require manufacturers | 2 |
| reported age | 2 |
| national expanded | 2 |
| full manuscript | 2 |
| proven covid | 2 |
| greatly improve | 2 |
| biovigilance component | 2 |
| years ago | 2 |
| glass opacities | 2 |
| nasal swabs | 2 |
| pcr test | 2 |
| united kingdom | 2 |
| sector partnerships | 2 |
| indicates milliseconds | 2 |
| study drugs | 2 |
| presentation ecg | 2 |
| socioeconomic disadvantage | 2 |
| terminal ileum | 2 |
| effective assessment | 2 |
| qxkel ww | 2 |
| transfusion reactions | 2 |
| adaptive immune | 2 |
| time first | 2 |
| prevention website | 2 |
| intravenous famotidine | 2 |
| nucleic acid | 2 |
| noninvasive positive | 2 |
| drug resistant | 2 |
| control sars | 2 |
| acute phase | 2 |
| opioid agonist | 2 |
| multivariable logistic | 2 |
| users respond | 2 |
| large outbreak | 2 |
| face treatment | 2 |
| lower adoption | 2 |
| remains unknown | 2 |
| label use | 2 |
| series clinical | 2 |
| drug shortages | 2 |
| corona virus | 2 |
| disease course | 2 |
| looming threat | 2 |
| clinical use | 2 |
| safety concerns | 2 |
| raising concern | 2 |
| problem drinkers | 2 |
| infection covid | 2 |
| nasopharyngeal swab | 2 |
| illness severity | 2 |
| home quarantine | 2 |
| physician navigators | 2 |
| weekly report | 2 |
| tuberculosis extensively | 2 |
| research shows | 2 |
| rapid changes | 2 |
| erythrocyte sedimentation | 2 |
| tobacco treatment | 2 |
| event rate | 2 |
| median heart | 2 |
| physical examination | 2 |
| isolation rooms | 2 |
| time rt | 2 |
| often require | 2 |
| better science | 2 |
| pharmacy consumer | 2 |
| adverse event | 2 |
| potential effects | 2 |
| symptomatic infected | 2 |
| sick patients | 2 |
| evolving covid | 2 |
| mechanical ventilatory | 2 |
| termed coronavirus | 2 |
| sera option | 2 |
| major scale | 2 |
| time spent | 2 |
| potential exposure | 2 |
| experience mild | 2 |
| state agencies | 2 |
| consumer protection | 2 |
| facial expressions | 2 |
| admitted patients | 2 |
| ventilation system | 2 |
| vicious cycle | 2 |
| order spreading | 2 |
| fatality ratio | 2 |
| holistic approach | 2 |
| tissues associated | 2 |
| suggest using | 2 |
| virtual health | 2 |
| cytokine release | 2 |
| state health | 2 |
| oxygen flow | 2 |
| first time | 2 |
| adverse effects | 2 |
| us states | 2 |
| potentially guiding | 2 |
| positive surveillance | 2 |
| will discuss | 2 |
| thromboembolic events | 2 |
| see table | 2 |
| age groups | 2 |
| ucm frol | 2 |
| per drinking | 2 |
| underestimate illness | 2 |
| median respiratory | 2 |
| illness monitoring | 2 |
| ambulatory practice | 2 |
| expiratory pressure | 2 |
| nosocomial infection | 2 |
| meet criteria | 2 |
| elevated ldh | 2 |
| rapid spread | 2 |
| identified studies | 2 |
| plasma per | 2 |
| adaptive trials | 2 |
| applied decision | 2 |
| also need | 2 |
| community partners | 2 |
| cabin air | 2 |
| rural populations | 2 |
| translational research | 2 |
| systolic blood | 2 |
| nippv hospital | 2 |
| right panel | 2 |
| continually updated | 2 |
| lymphocytic leukemia | 2 |
| cdc recommends | 2 |
| societal inequities | 2 |
| migratory lung | 2 |
| screen patients | 2 |
| abdominal pain | 2 |
| chart review | 2 |
| key words | 2 |
| public policy | 2 |
| drinking day | 2 |
| past experience | 2 |
| severe obesity | 2 |
| particularly poor | 2 |
| organized system | 2 |
| will require | 2 |
| software platform | 2 |
| data demonstrate | 2 |
| long periods | 2 |
| test result | 2 |
| health agencies | 2 |
| data may | 2 |
| current coronavirus | 2 |
| white blood | 2 |
| input variables | 2 |
| rapid review | 2 |
| regulatory agencies | 2 |
| close proximity | 2 |
| younger patients | 2 |
| rapid switch | 2 |
| health clinical | 2 |
| vgw uz | 2 |
| sleep apnea | 2 |
| supplemental oxygen | 2 |
| fibrin deposition | 2 |
| carefully charted | 2 |
| baseline echocardiogram | 2 |
| department presentation | 2 |
| data collection | 2 |
| presentation affects | 2 |
| animal markets | 2 |
| also like | 2 |
| new treatment | 2 |
| become symptomatic | 2 |
| first published | 2 |
| posttraumatic stress | 2 |
| potential donors | 2 |
| telehealth including | 2 |
| telemedicine will | 2 |
| prospective study | 2 |
| intravenous pressor | 2 |
| complete subsequent | 2 |
| reported cases | 2 |
| greatly expanded | 2 |
| thank andrea | 2 |
| higher prognostic | 2 |
| mild symptoms | 2 |
| individual study | 2 |
| stemi activation | 2 |
| use equipment | 2 |
| bioactive elements | 2 |
| white coat | 2 |
| face exposure | 2 |
| via nasal | 2 |
| industry partners | 2 |
| indicates chronic | 2 |
| transmission occurred | 2 |
| viral genome | 2 |
| host cell | 2 |
| considered positive | 2 |
| mass index | 2 |
| infection spread | 2 |
| events requiring | 2 |
| preserve personal | 2 |
| multinational registry | 2 |
| received mechanical | 2 |
| laboratory findings | 2 |
| will required | 2 |
| study whether | 2 |
| staphylococcus aureus | 2 |
| user response | 2 |
| evidence supporting | 2 |
| evidence may | 2 |
| based therapy | 2 |
| clinic irb | 2 |
| study clinical | 2 |
| online pharmacy | 2 |
| aerosolized generating | 2 |
| patients met | 2 |
| median temperature | 2 |
| aact may | 2 |
| elevated troponin | 2 |
| interstate spread | 2 |
| based tools | 2 |
| tb transmission | 2 |
| positive covid | 2 |
| support center | 2 |
| thank vijay | 2 |
| especially important | 2 |
| essential workers | 2 |
| plasma use | 2 |
| significant increase | 2 |
| detected rapidly | 2 |
| isolated contacts | 2 |
| alternative approaches | 2 |
| fatal outcomes | 2 |
| organization website | 2 |
| rapidly caused | 2 |
| population impacted | 2 |
| hemodynamic instability | 2 |
| coronary revascularization | 2 |
| global health | 2 |
| associated coronavirus | 2 |
| better prepared | 2 |
| may need | 2 |
| group therapy | 2 |
| ppe personal | 2 |
| call attention | 2 |
| mainland china | 2 |
| cell entry | 2 |
| antiviral drugs | 2 |
| infected person | 2 |
| including video | 2 |
| greatly needs | 2 |
| decision tool | 2 |
| get nowhere | 2 |
| laboratory results | 2 |
| best evidence | 2 |
| rigorous analysis | 2 |
| clinical experience | 2 |
| limited due | 2 |
| unique features | 2 |
| initially tested | 2 |
| positive cases | 2 |
| global data | 2 |
| related diseases | 2 |
| type diabetes | 2 |
| inside college | 2 |
| various aspects | 2 |
| adipose tissue | 2 |
| deficient patients | 2 |
| minor salivary | 2 |
| unclear symptomatic | 2 |